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Bacterial infectious diseases are a leading cause of death. Pore-forming toxins (PFTs) 
are important virulence factors of Gram-positive pathogens, which disrupt the plasma 
membrane of host cells and can lead to cell death. Yet, host defense and cell membrane 
repair mechanisms have been identified: i.e., PFTs can be eliminated from membranes 
as microvesicles, thus limiting the extent of cell damage. Released into an inflammatory 
environment, these host-derived PFTs-carrying microvesicles encounter innate immune 
cells as first-line defenders. This study investigated the impact of microvesicle- or 
liposome-sequestered PFTs on human macrophage polarization in vitro. We show that 
microvesicle-sequestered PFTs are phagocytosed by macrophages and induce their 
polarization into a novel CD14+MHCIIlowCD86low phenotype. Macrophages polarized 
in this way exhibit an enhanced response to Gram-positive bacterial ligands and a 
blunted response to Gram-negative ligands. Liposomes, which were recently shown 
to sequester PFTs and so protect mice from lethal bacterial infections, show the same 
effect on macrophage polarization in analogy to host-derived microvesicles. This novel 
type of polarized macrophage exhibits an enhanced response to Gram-positive bacterial 
ligands. The specific recognition of their cargo might be of advantage in the efficiency of 
targeted bacterial clearance.
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inTrODUcTiOn
During infection, membrane damaging toxins are released by numerous bacterial pathogens 
and contribute significantly to their virulence (1). An important family of membrane perforat-
ing toxins are the cholesterol-dependent cytolysins (CDCs) consisting of more than 20 members, 
which are secreted by Gram-positive bacteria. Notable representatives are pneumolysin (PLY, from 
Streptococcus pneumoniae), and streptolysin O (SLO, from Streptococcus pyogenes), which insert into 
host cell membranes and form large oligomeric pores that allow the leakage of cytoplasmatic pro-
teins (2, 3). CDCs are secreted as water soluble molecules that become associated with the host cell 
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membrane either via a specific receptor and/or cholesterol-rich 
microdomains (4). Subsequently, the large multimers undergo 
structural changes and form large aqueous pores resulting in 
Ca2+ influx and cytoplasmic efflux (3).
In order to prevent cell death, a concerted action of Ca2+-
sensing protein, either directly repair the plasmalemma or acti-
vate the membrane repair machinery (5). Recent work from our 
laboratory showed that—in response to the rise in cytoplasmic 
Ca2+—the annexins, members of a phospholipid-binding protein 
family translocate to the plasmalemma, quarantine the toxin pore 
within a membrane fold, which is then shed into the extra-
cellular space (6). By this route, PLY-pores are actively removed 
from epithelial cell membranes (7). FACS analysis and cryo-
electronmicroscopy of PLY-microvesicles confirm an association 
of PLY-pores and annexin family members and demonstrated 
that 90% of the vesicles were smaller than 500 nm with a median 
size of 160 nm (7).
Myeloid immune cells (monocytes, macrophages, dendritic 
cells, and granulocytes) are first line defenders in infections and 
coordinate the host’s immune responses to pathogenic threats. 
Inflammation in bacterial infection is often triggered by pore-
forming toxin-induced epithelial damage and leads to the release 
of cytokines that activate and recruit immune cells (8). The 
innate immune system recognizes pathogenic microorganisms 
by pathogen-associated molecular patterns (PAMPs) via pattern 
recognition receptors (PRRs). PAMPs [e.g., lipopolysaccharide 
(LPS); peptidoglycan (PGN); bacterial lipoproteins; unmethy-
lated repeats of CpG nucleic acids] represent molecular structures 
or molecules that are shared by most pathogenic microorgan-
isms. Detection of PAMPs by PRRs such as toll-like receptors 
(TLRs), retinoic acid-inducible gene-I-like receptors (RLRs), and 
nucleotide-binding oligomerization domain (NOD)-like recep-
tors (NLRs), triggers an immune response. For example, cell wall 
component LPS from Gram-negative bacteria is recognized by 
TLR4. The PRR for PGN, an important structural component of 
bacterial cell walls from mostly Gram-positive bacteria, is still 
a matter of debate. In mammals, there are two NLRs for rec-
ognition of PGN. NOD2 detects (Lys)-type PGN and muramyl 
dipeptide (MDP) as the minimal recognition structure, whereas 
NOD1 preferen tially senses the diaminopimelate-containing 
GlcNAc-MurNAc tri peptide muropeptide found mostly in 
Gram-negative PGN (9–11). While the role of NOD2 as a 
receptor for Gram-positive PGN is well documented, reports 
as to the role of TLR2 as a PGN receptor are contradictory. In 
some studies, TLR2 is described as a receptor for PGN (12–16). 
Other reports show that both MDP and highly purified PGN 
from several bacteria were not detected by TLR2 (17–19). Thus, 
there is a tendency to believe that TLR2 is not stimulated by 
PGN. The response of innate immune cells after PRRs ligation 
includes enhanced phagocytosis and cytokine production in 
monocytes/macrophages and neutrophils. It is not surprising 
that the responses of local immune cells (e.g., macrophages) 
and immediately recruited neutrophils and monocytes, are 
constitutively shaped by signals present at the site of infection 
(20). For instance, PAMPs and danger-associated molecular pat-
terns (DAMPs); which are released by damaged epithelial cells, 
have been shown to differentially polarize innate immune cells 
and thus shape the type of immune response (21). Polarization 
of macrophages leads to a modulation of their functional 
properties, ranging from pro-inflammatory (M1 phenotype) to 
anti-inflammatory (M2 phenotype) (22). These polarizations 
are not only driven by cytokines [i.e., interferon-γ (IFN-γ) and 
interleukin-4 (IL-4)] but also by immune complexes, and/or bac-
terial constituents (i.e., LPS) (23). M1-macrophages express high 
levels of pro-inflammatory cytokines [i.e., interleukin-1β, IL-1β, 
interleukin-6, IL-6, and tumor necrosis factor α (TNFα)] and 
participate in the induction of a Th1 response to prevent patho-
gen persistence. In contrast, M2-macrophages express different 
sets of receptors (i.e., CD206 and CD163) and produce primarily 
anti-inflammatory cytokines (i.e., interleukin-10, IL-10) (24). 
Thus, in broad sense, M1-macrophages act microbicidial and 
pro-inflammatory, whereas M2-macrophages are immunosup-
pressive. Recently, inflammation-driven polarization was also 
shown for neutrophils as they can acquire a monocytic pheno-
type and antigen-presenting cell functions (25, 26).
Plasma membrane repair results in the active shedding of copi-
ous amounts of plasma membrane particles containing inactivated 
toxins (6, 7). Despite the detailed elucidation of membrane repair 
mechanisms, it is not known whether the released microvesicles 
or the liposomal decoys that contain PFTs are able to activate 
immune cells (6, 7). In this study, we have analyzed the influence 
of inactivated PFTs, i.e., PLY, on the host’s innate immune system: 
taken up by host macrophages, microvesicles carrying neutral-
ized bacterial toxins display immunomodulatory effects, which 
lead to a hitherto unknown pattern of macrophage polarization. 
Their change in phenotype enables host macro phages to mount 
a specific response to Gram-positive inflammatory stimuli while 
Gram-negative stimuli are dampened. This novel macrophage 
phenotype might be primed to play a role in the rapid and efficient 
clearance of distinct classes of bacterial pathogens.
MaTerials anD MeThODs
reagents
Macrophage colony-stimulating factor (M-CSF), interleukin-4 
(IL-4), and IFN-γ were purchased from BioLegend (London, 
UK). LPS, PGN, and SLO were purchased from Sigma-Aldrich. 
Pam2CSK4 was purchased from InvivoGen (Toulouse, France). 
PLY was prepared as described (7) and bacterial endotoxins 
from protein stocks were removed by endotoxin removal resin 
(ThermoFisher Scientific, Reinach, Switzerland). Non-hemolytic 
ΔPLY protein mutant (ΔA146R147; amino acid deletions A146, 
R147) is described elsewhere (27). Liposomes (Cal02) used 
in these studies were a kind gift of Combioxin SA (Geneva, 
Switzerland).
ethics statement
Human buffy coats from healthy volunteers were purchased from 
the RedCross Switzerland (Bern, Switzerland). All subjects gave 
written informed consent in accordance with the Declaration 
of Helsinki. The buffy coats are pre-existing materials that were 
purchased with the ethics committee approval of the RedCross 
Switzerland (project P_103 to René Köffel). All obtained samples 
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were anonymized, thus no subject-identifying information was 
associated with the buffy coats.
cells
Primary human monocytes from buffy coats were isolated as 
previously described (25) and differentiated to macrophages 
in RPMI supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (Gibco, Life Technologies, Paisley, UK) and 1% 
penicillin–streptomycin (Gibco, Life Technologies, Paisley, UK) 
with M-CSF (75  ng/ml) for 7  days. Human embryonic kidney 
cells (HEK 293; ATCC CRL-1573; Manassas, VA, USA) were 
maintained in DMEM supplemented with 10% heat-inactivated 
FBS and 1% penicillin–streptomycin. Cell cultures were grown 
in 5% CO2 at 37°C.
Bacterial culture
Streptococcus pneumoniae D39 (laboratory strain) was cultured 
in BHI (Brain Heart Infusion Broth, Sigma-Aldrich, Buchs, 
Switzerland) at 37°C. For the generation of bacterial superna-
tants, bacteria grown to their stationary phase (OD600 = 1.0) were 
pelleted (5,000 × g) for 15 min. The supernatants were filtered 
through a syringe filter with a pore size of 0.2 µm (VWR, Dietikon, 
Switzerland) and incubated with liposomes (Cal02) to remove 
pore-forming toxin activity before re-stimulation experiments.
isolation of PlY-induced Microvesicles
HEK 293 cells (107) were gently washed with PBS. Microvesicle 
shedding was induced by treatment with PLY (2  µg/ml) in 
Ca-Tyrode’s buffer (140  mM NaCl, 5  mM KCl, 1  mM MgCl2, 
10 mM glucose, 10 mM HEPES, pH7.4, 2.5 mM CaCl2). The cells 
were incubated for 45 min at room temperature. Shed microvesi-
cles were isolated according to a protocol for extracellular vesicles 
(28). Briefly, conditioned medium was centrifuged at 300 ×  g 
for 10  min at 4°C to pellet cells. Supernatant was centrifuged 
at 2,000 ×  g for 20  min at 4°C (2  k pellet), transferred to new 
tubes, and centrifuged in a 45 Ti rotor for 40 min at 10,000 × g 
(10 k pellet), and finally in a 90 Ti rotor (Beckman Coulter, Nyon, 
Switzerland) for 90 min at 100,000 × g (100 k pellet). The pel-
lets were re-suspended in Ca-Tyrode’s buffer for stimulation of 
macrophages.
Polarization of Macrophages
After 7  days, media from macrophage cultures was exchanged 
to RPMI supplemented with 2% heat-inactivated FBS and 1% 
penicillin–streptomycin. Polarization of the macrophages was 
induced as described (29). Briefly, polarization was induced by 
100 ng/ml LPS plus 25 ng/ml IFN-γ (for M1 state), 20 ng/ml IL-4 
(for M2 state), PLY-microvesicles, PLY-liposomes, or liposomes 
only for 48 h.
Flow cytometry
Flow cytometry analysis was performed as described (25). The 
following murine monoclonal antibodies (mAbs) were used for 
FACS: unconjugated mAbs for TLR2 and TLR4; FITC-conjugated 
mAbs specific for CD206, CD83; phycoerythrin (PE)-conjugated 
mAbs specific for CD86, allophycocyanin-conjugated mAb 
specific for CD14; PerCP-Cy5.5-conjugated mAbs specific for 
CD163; PE-Cy7-conjugated mAb specific for HLA-DR. All 
antibodies and istotype control mAbs were purchased from 
BioLegend (London, UK). FACS analyses were carried out on 
LSRII cytometers (BD Instruments, San Jose, CA, USA). Data 
were analyzed with FlowJo software (LLC, Ashland, OR, USA).
Western Blot
Proteins from equal numbers of cells were separated by SDS-
Page and blotted onto polyvinylene difluoride membrane 
(PVDF) (Millipore, Billerica, MA, USA). For preparation of 
whole cell extracts, cells resuspended in sample buffer (0.5  M 
Tris–HCl pH 6.8; 40% glycerol; 4% SDS; 5 µl/ml bromphenol-
blue; 5% beta-mercaptoethanol) and lysed by heating at 95°C 
for 10 min. Proteins resolved by SDS-PAGE were transferred to 
PVDF membranes, which were probed with monoclonal anti-
PLY (Santa Cruz) followed by horseradish peroxide-conjugated 
goat anti-mouse IgG (H + L) antibodies (GE healthcare, Little 
Chalfont, UK). Protein detection was performed with the 
chemiluminescent substrate SuperSignal Quantum (Advansta, 
Menlo Park, USA) on a luminescent image analyzer (Witec AG, 
Switzerland).
real-Time rT-Pcr
Total RNA was isolated using the RNeasy Micro Kit (Qiagen, 
Hilden, Germany). For real-time RT-PCR analysis, the SYBR 
Green detection system was used (Quanta Biosciences, Beverly, 
MA, USA). All primers were designed using the Primer3 design 
tool. The following primer pairs were used for RT-PCR: TNFα 
5′-AGCCTCTTCTCCTTCCTGATCGTG-3′ (forward)/5′-GGC 
TGATTAGAGAGAGGTCCCTGG-3′ (reverse); CCL5 5′-TACA 
CCAGTGGCAAGTGCTC-3′ (forward)/5′-TGTACTCCCGAA 
CCCATTTC-3′ (reverse); SOCS1 5′-TGTTGTAGCAGCTTAAC 
TGTATC-3′ (forward)/5′-AGAGGTAGGAGGTGCGAGT-3′ 
(reverse); SOCS3 5′-CACTCTTCAGCATCTCTGTCGGAAG-3′ 
(forward)/5′-CATAGGAGTCCAGGTGGCCGTTGAC-3′ 
(reverse); STAT1 5′-TGGGTTTGACAAGGTTCTT-3′ (forward)/ 
5′-TATGCAGTGCCACGGAAAG-3′ (reverse); GAPDH 5′-GAA 
ATCCCATCACCATCTTCCAGG-3′ (forward)/5′-CGCGGCC 
ATCACGCCACAGTTTCC-3′ (reverse); NOD1 5′-CAGAGT 
CTCACCCCCACATT-3′ (forward)/5′-CGGCCGAGAAGTAG 
TCATTC-3′ (reverse); NOD2 5′-ATCTTCACACCGTCCCAGA 
G-3′ (forward)/5′-GCCAATGGGACTGGTAATTC-3′ (reverse). 
Expression profiling was performed in a 96-well format on the 
StepOne™ Real-Time PCR System (Applied Biosystems, Foster 
City, CA, USA). Data were analyzed using StepOne software 
for relative quantification. The expression of target genes was 
normalized to GAPDH.
immunohistochemistry
5 × 104 monocytes were differentiated to macrophages in cham-
berslides (Lab-Tek, Germany) for 7 days with M-CSF (75 ng/ml), 
fixed with 2% paraformaldehyde and permeabilized with ice-cold 
acetone. The cells were labeled with a polyclonal antibody against 
NFkB (Santa Cruz Biotechnology, USA) and a polyclonal, Cy3-
tagged secondary antibody (Jackson Immunoresearch, Suffok, 
UK). Nuclei were stained with Hoechst 33248, and slides were 
mounted using mounting medium (Agilent, Santa Clara, CA, 
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USA). Cells were analyzed using a confocal microscope Zeiss 
LSM880 and imaged using Zen software (Zeiss, Germany).
cytokine Measurement
Screening for cytokines secreted from macrophages was per-
formed by hybridizing conditioned medium with antibody-
coated membranes (human cytokine antibody array-membrane, 
Abcam, Cambridge, MA, USA) according to the manufacturer’s 
instructions. Briefly, macrophages were stimulated for 48 h and 
the culture supernatants were pooled and then hybridized to the 
array membrane. A biotin-conjugated second antibody was used 
and cytokines were detected by HRP-conjugated streptavidin. 
Signals were quantified by a luminescent image analyzer (Witec 
AG, Switzerland). Additional quantifications were performed 
using the Bio-Plex Pro™ assay according to manufacturer’s 
protocol. Measurement was performed on a Bio-Plex100 with 
Bio-Plex Manager 6.1 software (Bio-Rad, Hercules, CA, USA).
Phagocytosis assay
A phagocytosis assay was performed using E. coli-expressing 
EGFP-PLY as described (25). In brief, macrophages (5 × 105 each) 
were incubated with EGFP-E. coli for 30 min at 37°C and on ice 
and phagocytic capacity was determined by FACS after quench-
ing of surface bound fluorescent signal with 0.02% Trypan-blue. 
In addition, microscopic examination confirmed intracellular 
EGFP-E. coli signals.
electron Microscopy
Cells were fixed with 2% paraformaldehyde, 2.5% glutaraldehyde 
in 0.1 M sodium cacodylate buffer, pH 7.2, washed in the same 
buffer, and post-fixed in 1% potassium ferrocyanide reduced 
osmium textroxide as described (30). The samples were then 
dehydrated through a series of ethanol. Epon-embedded ultra-
thin sections were examined with a Tecnai spirit (FEI, Eindhoven, 
Netherlands).
statistics
Numerical data are expressed as mean values together with the 
SE. The statistical analyses were performed using GraphPad 
Prism7 software (GraphPad Software, La Jolla, CA, USA). Signi-
ficant differences are marked with asterisks.
resUlTs
stimulation of human Macrophages With 
host-Derived PlY-Bearing Microvesicles 
induces Phenotypic changes
Ectosomes and membrane vesicles are implicated in short and 
long distance intercellular communication and are attributed 
with immunomodulatory effects by acting primarily on immune 
cells (31–33). Recent results showed that microvesicles (below 
500 nm of size), with inactivated toxin pores are released dur-
ing membrane repair aiding cellular survival (7). We isolated 
PLY-microvesicles according to a recently established protocol 
by high-speed centrifugation and cryo-electronmicroscopy 
confirmed an association of PLY-pores with microvesicles (7, 28). 
Western blot analysis showed the presence of PLY-pores in the 
10 k fraction. However, enrichment of PLY-pores was particularly 
noticeable in the 100 k fraction (Figure 1A). Next, we stimulated 
macrophages either with the 10  k or the 100  k fraction and 
analyzed their phenotype after 48  h. Macrophages stimulated 
with the 10  k microvesicle fraction showed a slight, albeit not 
significantly higher expression of MHCII. In contrast, the 100 k 
microvesicles fraction induced a CD14+MHCIIlow phenotype 
(Figure  1B). In addition, a non-significant downregulation of 
the mean fluorescence intensity (MFI) of CD86, was observed. 
Moreover, the stimulation with PLY-microvesicles (100 k) induced 
a strong secretion of IL-6 and a moderate one after stimulation 
with the 10  k fraction (Figure  1C). PLY-microvesicle induced 
macrophages also produced high amounts of IL-1β, TNFα, 
CCL5, CCL8, and CCL1, which resembles a pro-inflammatory 
macrophage signature (Figure 1C, lower panel). In contrast to the 
pro-inflammatory signature, these macrophages showed a down-
regulation of MHCII and co-stimulatory receptor CD86, which 
is attributed to M2-polarization (Figure S1 in Supplementary 
Material). However, a hallmark of M2-polarization, such 
as upregulation of CD206 and CD163, was not observed in 
these cells. Next, we re-stimulated PLY-microvesicle-induced 
CD14+MHCIIlow macrophages with PGN (Gram-positive ligand) 
or LPS (Gram-negative ligand). These analyses reveal a reduced 
immediate TNFα response after 6 h LPS re-stimulation in PLY-
microvesicle induced macrophages as compared to controls. 
Moreover, the re-stimulation with PGN induced higher TNFα 
levels in CD14+MHIIlow macrophages, which even exceeded the 
TNFα induction in PGN stimulated control cells (Figure  1D). 
Importantly, PLY-microvesicle induced macrophages also showed 
an enhanced immediate TNFα response to re-stimulation with 
supernatants from S. pneumoniae (Figure  1D). These bacterial 
supernatants contain a whole spectrum of Gram-positive PRR/
TLR ligands.
Taken together, our results demonstrate that PLY-pores 
bound to microvesicles induce macrophage polarization to a 
specific CD14+MHCIIlow phenotype. The cytokine response of 
these macrophages (i.e., increased TNFα) is specifically directed 
against Gram-positive bacterial ligands.
Uptake of sequestered PlY by human 
Macrophages
Liposomes can prevent host cell damage by sequestering PFTs and 
protect mice from lethal pneumococcal infections (34). In anal-
ogy to macrophage sensitivity to host-derived PLY-microvesicles 
(Figure  1), we investigated the polarizing effects of toxin- 
sequestering liposomes. Cholesterol-sphingomyelin liposomes 
were recently been shown to be able to sequester pore-forming 
toxins (PFTs), i.e., PLY or SLO, and thus protect THP-1 cells from 
lysis in in vitro experiments (34). Initially, we monitored the efficacy 
of these liposomes to protect macrophages from cell death by EGFP-
tagged PLY. Stimulation of macrophages with EGFP-PLY without 
liposomes showed rapid binding of PLY to the plasma membrane. 
In contrast, addition of liposomes before stimulation with EGFP-
PLY completely abolished toxin binding (Figure 2A). Liposome-
protected macrophages displayed intracellular accumulations of 
EGFP-PLY at later time points, which suggested phagocytosis 
FigUre 1 | Pneumolysin (PLY)-induced microvesicles generate phenotypic changes in human macrophages in vitro. PLY-pores shed on microvesicles (PLY-MV) 
were generated by HEK-293 cells by stimulation with 2 µg/ml purified PLY for 30 min. This protocol, using a sub-lytic PLY concentration, ensures efficient membrane 
repair induction in HEK-293 cells without causing substantial cell death (7). (a) Isolation of PLY-MV. PLY-MV were isolated by differential centrifugation from cell 
culture supernatants and fractions (2 k, 2,000 × g pellet; 10 k, 10,000 × g pellet; 100 k, 100,000 × g pellet) were analyzed by Western blotting with a monoclonal 
antibody against PLY. One representative blot of three independent experiments is shown. (B) Stimulation of macrophages with PLY-MV. Day 7 M-CSF induced 
human macrophages were stimulated with PLY-microvesicles. FACS analysis after 48 h stimulation showed a marked downregulation of MHCII and CD86 in  
CD14+ gated macrophages treated with PLY-MV (100 k MV) as compared to untreated controls (CTRL) or 10 k MV-treated cells. A representative FACS blot is 
shown. Mean fluorescence intensity (MFI) of MHCII and CD86 of CD14+ gated cells were subjected to statistical analysis (100 k MV; mean ± SD; n = 5; *p < 0.05; 
unpaired t-test; two-tailed). (c) Cytokine profile of PLY-MV induced macrophages. Macrophages were stimulated as in (a) and IL-6 production was determined after 
48 h from culture supernatants using Bio-Plex (BioRad, Mean ± SD; n = 5; ***p < 0.001; unpaired t-test; two-tailed) or for global cytokine analysis Abcam cytokine 
arrays with pooled supernatants from three independent experiments were performed (heat-map; lower panel). Densitometric analysis were accomplished using the 
ImageJ protein analyser macro [written by G. Carpentier, 2010; http://rsb.info.nih.gov/ij/macros/toolsets/Protein%20Array%20Analyzer.txt]. Only cytokines with at 
least threefold difference between CTRL and 100 k PLY-MV were evaluated. (D) Re-stimulation of PLY-MV induced macrophages. Re-stimulation was performed 
with 100 ng/ml LPS, 1 µg/ml peptidoglycan, or supernatant from Streptococcus pneumoniae strain D39 (D39) for 6 h. RNA was isolated at time points 0 and 6 h. 
RT-PCR analysis was performed using primers for TNFα and SYBR green RT-PCR kit. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a reference 
gene (mean ± SD n = 5).
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of toxin-bearing liposomes. In order to monitor toxin uptake, 
liposomes preincubated with EGFP-PLY were used to stimulate 
macrophages. FACS and microscopic analysis showed that 
PLY-liposomes are phagocytosed by macrophages within 1–4 h 
after co-incubation (Figure  2B; Figure S2A in Supplementary 
Material). Ultrastructural analysis of macrophages stimulated 
with PLY-liposomes showed an increased number of lysosomes 
in these cells as compared to liposome-alone stimulated mac-
rophages, thus suggesting an activated macrophage phenotype 
(Figure S2B in Supplementary Material) (35). NfkB represents a 
key factor in the activation of macrophages that can trigger either 
M1 or M2 macrophage polarization (36, 37). NfkB translocated 
to the nucleus only after stimulation of macrophages with 
PLY-liposomes for 4 h whereas liposomes without toxin (=empty 
liposomes) did not elicit NfkB translocation (Figure 2C). These 
data suggest that PLY-pores bound to liposomes can be phago-
cytosed and are sensed by host macrophages. Importantly, since 
such inactivated PLY-pores lack cell damaging capacity, they 
are able to transmit signals to macrophages without danger.
stimulation With PlY-Bearing liposomes 
induces Phenotypic changes in 
Macrophages
Next, we investigated whether PLY-liposomes induce changes in 
surface marker expression and cytokine production similar to 
FigUre 2 | Human macrophages sense pneumolysin (PLY)-bearing liposomes. (a) PLY does not bind to macrophages in the presence of cholesterol:sphingomyelin 
liposomes. Day 7 M-CSF differentiated macrophages, either pre-incubated with liposomes (Lipo) or left untreated, were stimulated with 4 µg/ml EGFP-PLY and  
serial confocal imaging was performed. Images from T = 2 min post PLY additions are shown. The toxin binds exclusively to untreated macrophages. (B) Uptake  
of sequestered PLY on liposomes by human macrophages in vitro (arrow). Human primary macrophages were stimulated with EGFP-PLY-liposomes and analyzed  
at T = 4 h by confocal microscopy for intracellular EGFP-PLY (bar 10 µm). (c) Stimulation of macrophages with PLY-Lipo induces NfkB translocation from the 
cytoplasm into the nucleus. Day 7 M-CSF differentiated macrophages were stimulated with PLY-Lipo for 4 h. Afterward, cells were fixed, permeabilized, and  
stained with a monoclonal antibody against NfkB (red) and Hoechst (chromatin, blue).
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PLY-microvesicle induced changes (Figure 1). These liposomes, 
which were shown to efficiently bind PLY (34), would serve as 
presenting platforms for detoxified PLY in analogy to membrane- 
repair induced microvesicles. PLY-liposome stimulation indu-
ced a downregulation of MHCII and CD86 (Figure  3A). As 
observed for PLY-microvesicle-stimulated macrophages, the M2 
phenotype-associated expression of CD206 and CD163 was also 
not induced in PLY-liposome stimulated cells (Figure S1B in 
Supplementary Material). PLY-liposome stimulated macrophages 
showed a robust increase in IL-6 production, comparable to 
IL-6 induction in PLY-microvesicle simulated macrophages 
(Figure 3B versus Figure 1C). Thus, PLY-liposome stimulation of 
macrophages phenocopies the effects observed with host-derived 
PLY-microvesicles in terms of downregulation of MHCII and 
IL-6 induction.
The induction of IL-6 secretion argues against an anti-
inflammatory M2-macrophage phenotype in which IL6 is not 
induced. However, IL-6 levels are also not as elevated as in a pro-
inflammatory M1-macrophage (Figure S3A in Supplementary 
Material).
To exclude that contaminating active PLY induces the 
observed effects on macrophages, we made use of a non-toxic 
mutated version of PLY (A146R147; amino acid deletions A146, 
R147; ΔPLY). ΔPLY protein mutant is capable of forming oli-
gomers on membranes but lacks pore-forming activity (7, 27). 
Thus, ΔPLY protein was incubated with liposomes in analogy 
to the protocol used for wild-type PLY. Next, macrophages were 
stimulated with ΔPLY-liposomes or ΔPLY protein alone. After 
48 h, CD14+ gated macrophages were analyzed for MHCII and 
CD86 expression. ΔPLY-liposome stimulated macrophages 
showed a downregulation of MHCII and CD86 comparable to 
wild-type PLY liposome stimulated macrophages (Figure S3B in 
Supplementary Material versus Figure 3A). Thus, pore-forming 
activity is not accounting for phenotypic changes in macrophages 
stimulated with PLY. Moreover, ΔPLY protein alone stimulated 
macrophages exhibit a similar phenotype. High IL-6 secretion 
in ΔPLY-liposome or ΔPLY alone stimulated macrophages 
showed no differences to PLY-liposome stimulated macrophages 
(Figure S3C in Supplementary Material).
Pathogen-associated molecular patterns are sensed by mac-
rophages through PRRs, e.g., TLRs, NLRs, and RLRs. Bacterial 
cell wall components, such as LPS from Gram-negative bacteria 
are recognized by TLR4, or lipoproteins from Gram-positive 
bacteria are recognized by TLR2. FACS analysis of PLY-liposome 
stimulated macrophages revealed a significant increase of TLR2 
expression, whereas TLR4 levels remained constant (Figure 3C). 
RT-PCR analysis shows no increased TLR2 transcript abundance 
in PLY-liposome stimulated macrophages, indicating that 
elevated TLR2 surface levels are due to a posttranscriptional effect 
(Figure S4A in Supplementary Material). Moreover, also TLR1, 
TLR4, TLR5, and TLR6 expression levels remained unchanged 
in PLY-liposome stimulated macrophages as compared to control 
cells (Figure S4A in Supplementary Material). Detection of cell 
wall component PGN from Gram-positive bacteria is executed 
by NLRs, i.e., NOD1 and NOD2 (38). In particular, NOD2 was 
shown to sense MDP, whereas NOD1 detects muropeptides found 
mostly in PGN from Gram-negative bacterial species (9–11). 
RT-PCR analysis of PLY-liposome induced macrophages showed 
a significant increased expression of NOD2, but not NOD1, 
as compared to control macrophages (Figure  3D). These data 
FigUre 3 | Pneumolysin (PLY)-bearing liposomes induce phenotypic changes in human macrophages in vitro. PLY-bearing liposomes (PLY-Lipo) were produced  
by pre-incubation of 40 µg/ml cholesterol:sphingomyelin liposomes with 4 µg/ml PLY for 10 min at room-temperature. This protocol efficiently sequesters the total 
amount of added toxin and neither cytotoxicity nor binding of free PLY to cultured cells is observed (see Figure 2a). (a) PLY-liposomes induce a downregulation of 
MHCII and CD86 in macrophages. Day 7 M-CSF differentiated human macrophages were stimulated with PLY-liposomes (PLY-Lipo), liposomes without PLY (Lipo)  
or left untreated (CTRL) and analyzed by FACS gated for CD14+ macrophages after 48 h. PLY-Lipo stimulated macrophages showed a marked downregulation of 
MHCII and CD86 as compared to control cells (untreated or liposomes only; Lipo). A representative FACS blot of one of three independent experiments is shown. 
Mean fluorescence intensity of MHCII and CD86 of CD14+ gated cells of three independent experiments are shown (mean ± SD, n = 5; *p < 0.05; unpaired t-test; 
two-tailed). (B) PLY-liposomes induce IL-6 production in macrophages. Human macrophages were stimulated as in (a) and IL-6 production was determined  
after 48 h from culture supernatants performing Bio-Plex assays (BioRad). IL-6 production is shown to be significantly enhanced in PLY-Lipo stimulated 
macrophages (mean ± SD; n = 7; **p < 0.005; unpaired t-test; two-tailed). (c) PLY-liposomes induce TLR2 expression in macrophages. Day 7 M-CSF  
differentiated human macrophages were stimulated with PLY-Lipo or liposomes only (Lipo) and analyzed by FACS gated for CD14+ macrophages after 48 h. 
PLY-Lipo stimulated macrophages showed a significant increase in TLR2 as compared to control cells (liposomes only; Lipo). Percentages of TLR2- and TLR4-
expressing CD14+ macrophages are shown (mean ± SD; n = 6; *p < 0.05; paired t-test; two-tailed). (D) PLY-liposomes induced macrophages express increased 
levels of NOD2. Day 7 M-CSF differentiated human macrophages were stimulated with PLY-Lipo or liposomes only (Lipo) for 48 h. RNA was isolated and RT-PCR 
was performed to analyze expression levels of NOD1 and NOD2 in these cells. PLY-liposome induced macrophages showed a significant increase in NOD2 
expression as compared to control cells (liposomes only; Lipo). NOD1 levels remained unchanged (mean ± SD; n = 7; *p < 0.05; paired t-test; two-tailed).
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suggest that inactivated PLY-pores on liposomes induce a specific 
CD14+MHCIIlowCD86lowTLR2+NOD2+ macrophage phenotype 
distinct from M1 or M2 phenotypic polarization. These data also 
demonstrate that the signal is elicited by the inactivated toxin and 
not by constituents of the cell-derived, membrane repair-induced 
microvesicles.
FigUre 4 | Pneumolysin (PLY)-liposome induced macrophages respond differentially to PRR ligands. Day 7 M-CSF induced human macrophages were stimulated 
with PLY-liposomes (PLY-Lipo) or liposomes only (Lipo) for 48 h. After stimulation, cell media was removed, macrophages were washed once, and re-stimulated with 
a TLR4 ligand (LPS), a TLR2 ligand (Pam2CSK4), a NLR ligand (PGN), or supernatant from Streptococcus pneumonia strain D39 (D39). (a,B) PLY-liposome induced 
macrophages show an enhanced response to Gram-positive PRR/TLR ligands. Re-stimulation of PLY-Lipo induced macrophages was performed with 100 ng/ml 
LPS, 1 µg/ml Pam2CSK4, 1 µg/ml PGN, or supernatants from Streptococcus pneumonia D39 for 6 h. IL-6 production was analyzed by collecting supernatants at 
6 h and performing Bio-Plex measurements (mean ± SD, n = 6; *p < 0.05, **p < 0.005, paired t-test, two-tailed). (c,D) TNFα upregulation in PLY-liposome induced 
macrophages is increased in response to Gram-positive PRR ligands. (c) PLY-Lipo induced macrophages were re-stimulated as in (a) and RNA was isolated at  
time points 0 and 6 h. RT-PCR analysis was performed using primers for TNFα and SYBR green RT-PCR kit. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
served as a reference gene (mean ± SD, five donors; *p < 0.05, paired t-test, one-tailed). (D) PLY-Lipo induced macrophages were re-stimulated with supernatants 
from S. pneumoniae strain D39 and RNA was isolated at time points 0 and 6 h. RT-PCR analysis was performed using primers for TNFα and CCL5. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) served as a reference gene. Mean ± SD of five independent experiments and donors are shown (*p < 0.05, paired t-test, 
one-tailed).
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PlY-liposome Pre-stimulated 
Macrophages show a Biased response  
to gram-Positive Versus gram-negative 
Bacterial ligands
Macrophages, which recognize pathogenic bacteria by PRRs 
respond with phagocytosis and/or inflammatory cytokine pro-
duction. Macrophage polarization induces an increase (M1) or 
decrease (M2) in phagocytosis (39–41). Analysis of phagocytic 
capacity in PLY-liposome induced macrophages using GFP-E. coli 
showed an equally high phagocytotic efficiency in PLY-liposome 
treated versus empty liposome treated macrophages (Figure S4B 
in Supplementary Material). Since PLY-liposome stimulation 
of macrophages induces TLR2 in favor of TLR4, we examined 
how PLY-liposome induced macrophages respond to TLR liga-
tion. Re-stimulation of PLY-liposome induced macrophages 
with LPS led to identical IL-6 secretion as in cells stimulated 
with empty liposomes (Figure  4A). In contrast, re-stimulation 
of PLY-liposome induced macrophages with Pam2CSK4, a syn-
thetic diacylated lipopeptide that is sensed by TLR2, induced a 
significantly enhanced IL-6 production as compared to control 
macrophages (Figure  4A). Moreover, re-stimulation of these 
macrophages with PGN led to a significantly enhanced IL-6 
production (Figure 4A). Stimulation of PLY-liposome induced 
macrophages with supernatants from S. pneumoniae D39 
(virulent serotype 2) induced a massive IL-6 response, higher 
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than in cells treated with empty liposomes (Figure 4B). TNFα 
represents another important cytokine induced in pneumococcal 
pneumonia (42). LPS re-stimulation of empty liposome-induced 
macrophages showed immediate TNFα upregulation as expected; 
however, no induction of TNFα in PLY-liposome induced mac-
rophages was observed (Figure  4C). When re-stimulated with 
PGN, the induction of TNFα within 6 h was increased in PLY-
liposome induced macrophages versus control cells, although 
not significantly (Figure 4C). In contrast, re-stimulation of these 
cells with Pam2CSK4 had no significant effect on the expression 
levels of TNFα (Figure 4C). Re-stimulation with S. pneumoniae 
D39 supernatants confirmed the observed preferential reaction 
to Gram-positive bacterial ligands of PLY-liposome induced 
macrophages and showed an enhanced induction of TNFα 
(Figure  4D). In addition, the expression of CCL5, an impor-
tant chemokine, which attracts neutrophils in pneumococcal 
infections (43), was strongly upregulated in re-stimulated PLY-
liposome-induced macrophages, whereas controls did not induce 
CCL5 expression (Figure 4D). In contrast, when challenged with 
LPS, TNFα induction was inhibited and no increase in IL-6 
was observed. These data suggest that PLY-liposome induced 
CD14+MHCIIlowCD86lowTLR2+NOD2+ macrophages display 
an enhanced response to Gram-positive ligands and a blunted 
response to Gram-negative microbial products. Our data thus 
indicate that macrophages can be polarized in response to bacte-
rial toxins, even when they are presented in an inactive state.
Toll-like receptors signaling provides positive signals 
in immune cell activation and is counter-regulated by a 
negative feed-back loop executed by Suppressor of Cytokine 
Signaling (SOCS) and Signal Transducer and Activator of 
Transcription (STAT) proteins (44). Therefore, we analyzed 
these regulatory molecules in CD14+MHCIIlowCD86lowTLR2+ 
macrophages. Compared with control cells, PLY-liposome 
induced macrophages display increased steady-state levels of 
SOCS1, SOCS3, and STAT1, which may explain the blunted 
response to LPS by these cells (Figure S4C in Supplementary 
Material).
stimulation of Macrophages With Diverse 
Pore-Forming Toxin-Bearing liposomes 
induces selective Phenotypic changes
Since numerous Gram-positive bacteria produce specific CDCs, 
we analyzed the macrophages’ response to SLO (from S. pyo-
genes). In analogy to PLY, SLO-pores are efficiently sequestered by 
liposomes (34). Thus, we generated SLO-bearing liposomes and 
stimulated macrophages according to our previous protocols. In 
contrast to PLY-liposomes, SLO-liposomes induced an upregu-
lation of MHCII and CD86 and no increase in IL-6 secretion 
(Figures 5A,B). Thus, the macrophage phenotype after stimula-
tion with SLO-liposomes (CD14+MCHIIhiCD86hi) clearly differed 
from stimulation with PLY-liposomes (CD14+MCHIIlowCD86low, 
Figure  3A). Cytokine profiling of SLO-liposome stimulated 
macrophages revealed a distinct cytokine production pattern 
as compared to PLY-liposome stimulated macrophages (Figure 
S5A in Supplementary Material). SLO-liposome stimulated 
macrophages show a moderate upregulation of IL-10, CCL8, 
and CCL15 in comparison to control cells. In line with a differ-
ent macrophage polarization, re-stimulation of SLO-liposome 
induced macrophages with S. pneumoniae D39 supernatants 
resulted in a lower secretion of IL-6 than in those stimulated 
with PLY-liposomes (Figure  5C). Interestingly, IL-6 secretion 
of SLO-liposome stimulated macrophages after re-stimulation 
exceeded that of control cells (9.2-fold increase versus control, 
Figure  5C). Induction of TNFα in SLO-induced macrophages 
after re-stimulation was comparable to PLY-liposome induced 
macrophages, whereas there was no induction of CCL5 in SLO-
induced macrophages (Figure S5B in Supplementary Material). 
Interestingly, SLO-induced macrophages produced high amounts 
of IL-6 when re-stimulated with LPS. Taken together, these data 
show that SLO-liposomes induce macrophage polarization to a 
CD14+MHCIIhiCD86hi phenotype distinct from PLY-liposome 
induced macrophages (CD14+MHCIIlowCD86low). Moreover, 
SLO-liposome induced macrophages show an enhanced IL-6 
secretion in response to LPS, but only a moderate IL-6 produc-
tion when re-challenged with S. pneumoniae D39 supernatants 
(Figure S5C in Supplementary Material; Figure 5C). Thus, these 
data indicate that neutralized PFTs convey distinct polarization 
signals.
DiscUssiOn
We show that inactive PFTs, sequestered by liposomes or shed 
on microvesicles during membrane repair processes, polarize 
macrophages to enhance responses to Gram-positive PAMPs.
Although the innate immune response to different bacteria is 
thought to be non-specific, this short-cut in toxin identification 
appears to enable an early adaption of the immune response to 
the pathogen (see model in Figure 6).
The type of polarization of macrophages is critical for the 
resolution or non-resolution of an inflammatory condition. 
Polarization into distinct subpopulations depends on the 
inflammatory environment (i.e., cytokines, microbial products, 
immunocomplexes) (23). We show that PLY-liposome stimulated 
macrophages polarize to a CD14+MHCIIlowCD86lowTLR2hiNOD2+ 
phenotype. M1-macrophages express high levels of MHCII and 
CD86 whereas downregulation of these molecules was shown 
to be associated with M2-polarization (45, 46). It is important 
to note that none of the other established markers for M2 mac-
rophage polarization (i.e., CD206, CD163) are upregulated after 
stimulation with sequestered PLY. The cytokine pattern elicited 
by sequestered PLY resembles a pro-inflammatory macrophage 
signature, i.e., production of IL-1β, TNFα, IL-6, CCL5, CCL8, and 
CCL1, for attraction of innate and adaptive immune cells. Thus, 
the macrophage phenotype induced by inactive PLY is novel, 
but closely resembles a pro-inflammatory phenotype (despite 
the downregulation of MHCII and CD86) at least in response to 
Gram-positive PAMPs.
The pore-forming activity of PLY is not essential for initiat-
ing the phenotypic changes in macrophages, as a non-hemolytic 
ΔPLY mutant protein, similarly induces downregulation of 
MHCII and CD86 and secretion of IL-6. These data supports 
that PLY protein itself, either neutralized on liposomes or shed 
FigUre 5 | Streptolysin O (SLO)-bearing liposomes-induced macrophages display a phenotype distinct from Pneumolysin (PLY)-liposome induced macrophages. 
Day 7 M-CSF induced human macrophages were stimulated with PLY-liposomes (PLY-Lipo) or SLO-Liposomes (SLO-Lipo) for 48 h. Equal amounts (4 µg/ml) of PLY 
or SLO protein were incubated with 40 µg/ml liposomes for 10 min at room-temperature before addition to the cells. (a) SLO-liposomes induce an upregulation of 
MHCII and CD86 in macrophages. Macrophages were stimulated with PLY-Lipo, SLO-Lipo, or liposomes without pore-forming toxin (Lipo) and analyzed by FACS 
gated for CD14+ cells after 48 h. Expression levels of MHCII and CD86 were evaluated compared to control cells (liposomes only; Lipo). A representative FACS  
blot of one of three independent experiments is shown. Mean fluorescence intensity of MHCII and CD86 of CD14+ gated cells of three independent experiments  
are shown (mean ± SD, n = 6; *p < 0.05, unpaired t-test, two-tailed). (B) SLO-liposomes stimulation does not induce IL-6 production in macrophages. Human 
macrophages were stimulated as in (a) and IL-6 production was determined after 48 h from culture supernatants performing Bio-Plex assay (mean ± SD, n = 5; 
*p < 0.05, paired t-test, two-tailed). (c) Re-stimulation of SLO-Lipo induced macrophages with Streptococcus pneumonia supernatants. Human macrophages  
were stimulated with PLY-liposomes (PLY-Lipo) or SLO-liposomes (SLO-Lipo) for 48 h. After stimulation, cell media was removed, macrophages were washed once, 
and re-stimulated with supernatant from S. pneumonia strain D39 for 6 h. IL-6 production was analyzed by performing Bio-Plex measurements (mean ± SD, n = 4; 
*p < 0.05, paired t-test, two-tailed).
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microvesicles, can be recognized by macrophages and induce 
macrophage polarization. These data are in line with the immu-
nogenic properties of PLY protein, which have been proposed for 
use in pneumococcal vaccines (27, 47).
Whereas TLR4 levels remain unchanged, TLR2 and NOD2 
expression is increased in sequestered PLY stimulated macrophages. 
The importance of TLR2 in the defense against Gram-positive 
bacteria is well documented: TLR2-deficient mice are more sus-
ceptible to S. pneumoniae infection (48). Re-stimulation of these 
macrophages with Gram-positive PAMPs (S. pneumoniae D39  
supernatants) induced enhanced production of IL-6, TNFα, and 
CCL5. These cytokines have been assigned important functions in 
the resolution of S. pneumoniae infections (43, 49, 50). Although 
TLR4 expression does not change in CD14+MHCIIlowCD86low 
macrophages, these cells show a blunted TNFα induction in res-
ponse to Gram-negative LPS, whereas IL-6 secretion in response 
to LPS is not altered.
CD14+MHCIIlowCD86lowTLR2hiNOD2+ macrophages display 
an increased expression of SOCS1, SOCS3, and STAT1, known 
regulators of macrophage functions/cytokine responses. SOCS1 
was shown to inhibit TLR4 signaling, whereas SOCS3 regulates 
pro-inflammatory functions (51–53). Thus, an elevated expression 
of SOCS1 in PLY-liposome induced macrophages may reduce 
the LPS response of these cells with regard to TNFα induction.
It has been suggested that the interaction of PLY with TLR4 is 
critically involved in the innate immune response to S. pneumoniae:  
TLR4-mutant mice were more susceptible to lethal infection 
with PLY-positive pneumococci (54). LPS tolerance is induced 
via TLR4 signaling and is known to reduce phagocytic activity of 
macrophages and lower IL-6 secretion after LPS re-stimulation 
(55, 56). PLY-liposome induced macrophages possessed identi-
cal phagocytic capacity as control cells. Moreover, no differences 
in IL-6 response to LPS re-stimulation were observed. Thus, it 
is unlikely that the CD14+MHCIIlowCD86lowTLR2hi phenotype 
results from excessive PLY-TLR4 signaling, since this would 
lead to LPS tolerance and no IL-6 response after re-stimulation 
with LPS.
Host cell membrane repair mechanisms release microvesi-
cles that bear inactive PFT-pores (5). PLY-microvesicles induce 
macrophage polarization to a CD14+MHCIIlowCD86low pheno-
type, which leads to a preferential response to Gram-positive 
PAMPs. Thus, inactive PLY-pores on microvesicles from mem-
brane repair events serve as DAMPs, which might alert immune 
cells and shape the type of immune response elicited by infection 
FigUre 6 | The effect of inactivated pneumolysin (PLY)-pores on macrophages in an inflammatory environment. Pore-forming toxins (PFTs), such as PLY perforate 
the plasmalemma of host cells. Membrane repair is initiated and toxin pores are shed into the extracellular space in the form of microvesicles (7). Alternatively, the 
administration of specific liposomes sequesters the pore-forming toxin and protects the host cell from injury (34). PLY-pores on liposomes or on microvesicles 
(PFT-liposomes/microvesicles) are sensed by macrophages and prime macrophages to preferentially react against pore-forming toxin-producing Gram-positive 
bacteria, i.e., Streptococcus pneumoniae, with an increased production of IL-6 in response to PRR ligation (i.e., TLR2, NOD2) by Gram-positive ligands.
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with S. pneumoniae. If PFT-microvesicles are present in sufficient 
amounts in vivo to polarize macrophages in bacterial infections 
remains to be determined. However, in the local infection micro-
environment, e.g., in proximity to epithelial barriers, macrophages 
would be sensing sufficient amounts of PLY-microvesicles to induce 
polarization, as described for endogenous molecules released 
by damaged cells (DAMPs) that signal to macrophages (57).
Streptolysin O, produced by S. pyogenes, is another prominent 
pore-forming toxin of the cholesterol-dependent cytolysin-
family with similarities to PLY (1). Contrary to PLY-liposome 
polarization of macrophages, stimulation with SLO–liposomes 
induces a CD14+MHCIIhiCD86hi phenotype, low levels of IL-6, 
and an enhanced response against Gram-negative LPS. Moreover, 
the IL-6 production of CD14+MHCIIhiCD86hi macrophages in 
response to S. pneumoniae supernatant stimulation was similar 
to control macrophages. Thus, the macrophage polarization in 
response to inactive PLY on liposomes or microvesicles is unique 
and clearly differs from inactive SLO. These data suggests dif-
ferent recognition receptors on macrophages for distinct PFTs, 
which remain to be identified. Future experiments will also 
elucidate the protein domains/structures of distinct PFTs that 
drive macrophage polarization.
Our work shows that PLY-microvesicles or PLY-liposomes 
act as alarm (DAMPs)-like signals that polarize macrophages to 
preferentially respond to Gram-positive PAMPs. The liposomes 
used in this study, which sequester and neutralize PFTs, i.e., PLY 
or SLO, are currently in a phase II clinical trial as adjunctive 
therapy to antibiotics in severe streptococcal pneumonia (34). 
Our data provide a novel mode-of-action of these liposomes 
with trapped PFTs, especially on immune cells, which are key 
players in the host defense and in the coordination of immune 
responses against bacterial infections. Importantly, such inacti-
vated PLY-pores on microvesicles as well as on liposomes lack 
cell damaging capacity and thus are sensed without danger 
by immune cells. The fact that PLY-liposomes phenocopy the 
activation of macrophages with PLY-microvesicles suggests 
that a key signal for macrophage activation is delivered by the 
inactivated PLY-pores alone and not by microvesicle-associated 
proteins.
Thus, macrophages in immune responses to streptococcal 
infection may be activated/polarized through this novel signaling 
mechanism in order to initiate specific immune responses, pre-
sumably for the efficient clearing of distinct bacterial pathogens.
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